BRAF and neoplasm: Of note, low tumor cell content may prevent identification of the BRAF V600E mutation by molecular analysis and result in false-negative results, but this limitation has been shown to be overcome by the use of BRAF V600E monoclonal antibody [18,29,30,32,34].